Serum N-acetyl-β-D-glucosaminidase level assessment in type 2 diabetes mellitus patients with ischemic heart disease.
saleh, E., hassaan, M., mohamed, S., Mousa, M. (2023). Serum N-acetyl-β-D-glucosaminidase level assessment in type 2 diabetes mellitus patients with ischemic heart disease.. EKB Journal Management System, 29(1.1), 61-69. doi: 10.21608/zumj.2020.31340.1864
ehab ahmed saleh; mohammed mohammed hassaan; Samy hasan mohamed; Mayada Mohamed Mousa. "Serum N-acetyl-β-D-glucosaminidase level assessment in type 2 diabetes mellitus patients with ischemic heart disease.". EKB Journal Management System, 29, 1.1, 2023, 61-69. doi: 10.21608/zumj.2020.31340.1864
saleh, E., hassaan, M., mohamed, S., Mousa, M. (2023). 'Serum N-acetyl-β-D-glucosaminidase level assessment in type 2 diabetes mellitus patients with ischemic heart disease.', EKB Journal Management System, 29(1.1), pp. 61-69. doi: 10.21608/zumj.2020.31340.1864
saleh, E., hassaan, M., mohamed, S., Mousa, M. Serum N-acetyl-β-D-glucosaminidase level assessment in type 2 diabetes mellitus patients with ischemic heart disease.. EKB Journal Management System, 2023; 29(1.1): 61-69. doi: 10.21608/zumj.2020.31340.1864

Serum N-acetyl-β-D-glucosaminidase level assessment in type 2 diabetes mellitus patients with ischemic heart disease.

Zagazig University Medical Journal
Article 9, Volume 29, Issue 1.1, January 2023, Page 61-69  XML PDF (381.87 K)
Document Type: Review Articles
DOI: 10.21608/zumj.2020.31340.1864
View on SCiNiTO View on SCiNiTO
Authors
ehab ahmed saleh email 1; mohammed mohammed hassaan2; Samy hasan mohamed3; Mayada Mohamed Mousa4
1internal medicine, faculty of medicine. Zagazig university, mehalla kobra .Egypt
2Internal Medicine Faculty of Medicine- Zagazig University, zagazig city, Egypt
3Medical Biochemistry Faculty of Medicine- Zagazig University, Zagazigy, Egypt
4Lecturer of Internal Medicine, Zagazig University, Zagazig
Abstract
Abstract
Background
Ischemic heart disease has a great impact on morbidity and mortality in type2 diabetes mellitus patients. Type2Diabetes Mellitus (Type 2D.M) is risk factor for coronary atherosclerosis. N-acetyl-β-D-glucosaminidase (NAG) is an enzyme present in humans (IHD) in patients suffering from type 2 DM.
Patients and methods
cross-sectional study included 84 subjects; 21 healthy individuals, 21 patients with IHD; 21 with type 2 DM and 21 with type2DM with IHD, subjected to history taking, clinical examination, liver function tests, postprandial blood sugar, HbA1c, lipid profile, ECG, echocardiography, cardiac catheterization and carotid Doppler ultrasound. and N-acetyl –B-D-glucosaminidase level measurement
Results
There are a statistically significant differences between our groups as regard basic and laboratory data. There are differences between control group and diabetic group regarding WBCS (P=0.028), urea (p < 0.001), creatinine (p=0.003). AST,fasting, 2hour postprandial blood sugar and HBA1C (p < 0.001). There is a difference regarding NAG (p < 0.001). There are direct correlations between NAG and BMI, SBP, DBP, WBCS,, triglycerides, fasting, 2 hours postprandial blood sugar and HbA1c. The best cutoff of serum NAG in diagnosis of ischemia in diabetic patients is > 0.692 U/L, AUC of 0.949, sensitivity of 95% and specifcity of 90.91%. The best cutoff of serum NAG in diagnosis of ischemia in diabetic patients is > 6.77 U/L, AUC of 0.884, sensitivity of 90.48% and specifcity of 95.24%.
Conclusion
Level of serum N acetyl β D-glucosaminidase increases in type diabeticsmsuffering from ischemic heart disease.
Keywords
Keywords: type 2 diabetes mellitus; ischemic heart disease; acetyl beta D glucosaminidase
Statistics
Article View: 233
PDF Download: 86